Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.
about
Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesProphylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy.Trial Watch: Toll-like receptor agonists in oncological indications.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cellsProthymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceDendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.MyD88-dependent pro-inflammatory activity in Vi polysaccharide vaccine against typhoid promotes Ab switching to IgG.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyModulation of Innate Immune Responses via Covalently Linked TLR Agonists.Trial watch: Dendritic cell-based interventions for cancer therapyImmune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine.Use of defined TLR ligands as adjuvants within human vaccines.The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.Exploiting dendritic cells in the development of cancer vaccines.Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.Dendritic cell based vaccination strategy: an evolving paradigm.Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody.Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets.Trial Watch: Toll-like receptor agonists for cancer therapy.Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Potential applications for plasmacytoid dendritic cells in cancer immunotherapy.Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4.
P2860
Q26746887-EC389C8E-7153-4659-A30E-3DED4D979B23Q26772715-241F6C28-D8F0-4838-AF85-21F98C946279Q27323878-F01842FE-2B1F-4EB7-A9A9-D5DCE5628804Q33583613-48765F56-F9AF-4D93-B884-AF4B3F32C202Q33820931-9200DF2D-ED3C-4107-B97E-54384E242274Q33878578-41C946F4-5521-4EF1-8FFB-FBA2E1F11FC3Q34447679-F953DE3F-F413-4323-8411-238C514183C6Q34540737-333266CB-B5EC-4E87-BE56-60E2FC75F877Q34993170-9B3F4132-69DC-457D-AD9E-F48FD548C138Q35142813-6EA2F5D8-ED39-4152-9A9B-23D932E0F3FAQ35763478-ABFFCC1E-7FD9-4AF1-89A3-B6051A4ADC19Q36066380-C5364C11-AA20-42CD-82E7-A831EE06D4E6Q36194849-4F984FBB-C9AC-4A99-B812-EDBBBB774BFCQ36333881-BF6E24D0-8E2C-4693-8E4B-27634E3E1CFEQ36388529-E0DE8A4F-2E0C-4914-B0B0-8C43AD5BCCD0Q36992766-0B3A5005-5703-43DD-8F64-EAD1E00F7983Q37431320-D667B793-1109-4290-B13D-382A7D3BC791Q37686631-2AF3C08D-9B8B-444E-9ED7-5AB014822ECDQ37825528-5CD22D3D-FD29-44EA-A8FE-54308F407C08Q38124064-BFEB14CE-3DAF-4A85-B62A-253ABC709DD9Q38148774-6778DC99-58B4-4E40-91AE-C2FC5337787FQ38206571-BFE3DFEE-20FF-4DF9-83D0-EB630B1F481FQ38208309-54FA6390-178E-4DE6-8683-5C478CD90F50Q38691953-C16B580E-DC45-483E-B0D2-71439B6647A0Q38944175-2581DF8C-FA0C-4B60-A8F7-AFD869E9CA24Q40278311-BC5EBC11-E492-4717-80BC-A2D82839818CQ41569221-D789A026-D535-43EC-8436-2C26962D8E19Q41835523-7A61FC5D-BFCC-4DE7-836A-651AAA5ADFA1Q42969291-D90158A0-9A50-4E9A-B274-DDB215441363Q45921466-4294F0E3-B512-43D8-A4BD-AA9F6974AB4EQ47134263-B8BE6F6C-F471-4C3B-978F-03C748E649E0Q48356056-376305F9-2E23-44B6-8BE6-EB7676618845Q51050849-11524E72-A402-48D6-AF41-F230608F9A76Q55514821-DF16F63E-7E06-46C7-950E-A6612E714CC8
P2860
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@en
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@nl
type
label
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@en
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@nl
prefLabel
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@en
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@nl
P2093
P50
P1433
P1476
Commonly used prophylactic vac ...... ocyte-derived dendritic cells.
@en
P2093
Annechien J A Lambeck
Cornelis J A Punt
Daniel Benitez-Ribas
Danita Schuurhuis
Gosse J Adema
I Jolanda M de Vries
Maaike van Hout-Kuijer
P304
P356
10.1182/BLOOD-2009-11-251884
P407
P577
2010-04-27T00:00:00Z